Evaluation of a Rapid Detection Influenza Virus A Antigens Kit Using Paired Serum Antibody Test

Hangwei Chen,¹ Huimin Wang,² Xuehui Li,¹ Lanhua You,¹ Juan Wei,¹ and Weixian Shi³
¹Department of Respiratory Medicine, The Military General Hospital of Beijing PLA (The Chinese People’s Liberation Army, PLA), Beijing; ²Department of Respiratory Medicine, Beijing Pinggu Hospital, Beijing; ³Beijing Centers for Diseases Control and Prevention (CDC) & Centers for Preventive Medical Research, Beijing, China.

Received: January 30, 2012
Revised: April 2, 2012
Accepted: April 18, 2012
Corresponding author: Dr. Hangwei Chen, Department of Respiratory Medicine, The Military General Hospital of Beijing, PLA NO.5 Nanmencang, Dongcheng District, Beijing 100700, China. Tel: 86-010-66721167, Fax: 86-010-66721167 E-mail: hw-chen@hotmail.com

Purpose: To evaluate the feasibility for gold immunochromatographic assay (GICA) in rapid detection of influenza virus A infection. Materials and Methods: Seventy-three patients were enrolled. All patients contributed nasopharyngeal secretions and paired serum samples. Nasopharyngeal secretions was used for colloidal gold immunochromatographic rapid assay for influenza A virus immediately after the collection of specimen. Paired serum samples were used for the hemagglutination inhibition assay at the Centers for Disease Control and Prevention influenza network laboratory in Beijing. Results: Compare GICA test to hemagglutination inhibition (HI) assay, the Kappa value was 0.402 and the p value in the paired χ² test was higher than 0.05. Therefore, the difference was not statistically significant. The sensitivity of GICA was 50.0% and the specificity was 90.2%, and the negative predictive value was 90.2%. Conclusion: The sensitivity for Influenza A antigen detection by using GICA is relatively low, the specificity is relatively satisfactory.

Key Words: Influenza A virus, colloidal gold immunochromatographic assay, antibody, rapid test

INTRODUCTION

Influenza is induced by the influenza virus, which can be divided into type A, B and C according to the characteristics of nucleoprotein and matrix protein of the virus.¹ Among them influenza A virus is the most frequently seen virus with the highest virulence.² Influenza A causes both pandemics and epidemics. Humankind had suffered 3 times influenza pandemics induced by influenza A in 20 century,³ which killed millions of people. A subtype that had never been reported was a disassociation from infectious patients in Mexico and identified as a novel type A H1N1 Influenza virus strain in April 2009, and subsequently this virus spread to more than 90 countries.⁴ ⁶ Diagnosis and treatment on influenza normally rely on the clinical experiences of doctors, which sometimes can lead to misdiagnosis and antibiotic abusage. Expected clinical symptoms and laboratory examinations are badly needed for the di-
agnosis of early influenza, which has important significance for controlling the spread of influenza and reducing the hazards of diseases and antibiotic abuse. Currently, use of the rapid influenza test is recommended by the World Health Organization.

Cell culture, PCR and hemagglutination inhibition (HI) assay in serological detection have been well received as the “golden criteria” for confirming the infection of influenza virus. However, these methods are time and labor consuming, the requirements on technical conditions are high and thus not suitable for fundamental hospitals. Colloidal gold immunochromatographic assay (GICA) with membrane as the solid carrier is a kind of in vitro diagnostic technique that has been developed in recent years, this method has been used in the diagnosis of clinical diseases due to its convenience. Currently, there are several commercial influenza rapid diagnostic test kits available on the market, such as Binax NOW FluA and Flu B, Directigen Flu A, Flu OIA and QuickVue Influenza Test. However, all of these kits are relatively expensive and difficult to be widely used in resource-limited countries where the threat of influenza epidemic is generally greater and rapid tests are needed the most. Recently, a rapid influenza A virus test based on GICA assay was developed by ASCLE BioEngineering Company. The cost of this test is only a quarter of the currently available commercial influenza rapid testing kits. In a previous study, we compare the GICA kit result with the RT-PCR and viral culture, it showed that the consistency between the GICA test and virus culture assay is moderate, in reference to RT-PCR, GICA test demonstrated considerable high sensitivity (74%) and specificity (86%), with Kappa value being 0.61 and overall accuracy of 81%. In this study, we compared the result of GICA kit made by ASCLE BioEngineering, Inc. with serum hemagglutination inhibition antibody (HI antibody) because HI tests have been important for the epidemiological surveillance of influenza virus and has been received well by the scientific community.

MATERIALS AND METHODS

Subjects
Seventy three patients showing influenza like symptoms in the Department of Respiratory System in the General Hospital of Beijing military district from September 20, 2009 to March 20, 2010 were enrolled. The entities included acute upper respiratory tract infection, acute bronchitis, pneumonia, bronchial asthma, chronic cor pulmonale and others.

Nasopharyngeal secretions swabs were prepared upon hospitalization or in the early morning on the next day from the patients. On-spot GICA rapid detection was carried out and paired serum samples in the acute stage and the convalescence stage were also collected (1 mL each; interval of 10-18 days). The frozen paired serum samples from the 73 cases were sent to the laboratory in Beijing Disease Prevention and Control Center at 4°C in different batches, and the HI was carried out to detect three kinds of subtypes of HI antibody of Influenza A (novel H1N1, seasonal H1N1 and seasonal H3N2) within 24 hours. The tests as mentioned above were approved by the ethics committee of the hospital.

Methods

GICA test
GICA-based Influenza virus A Rapid Test Kits (GICA) were developed by ASCLE BioEngineering Company (National Drug Approval #: S20063095, Beijing, China). This test is a double antibody sandwich immunoassay that includes core protein monoclonal antibody and colloidal gold-labeled core antigen monoclonal antibody. In this study, the tests were all performed according to the manufacturer’s instructions, as follows: specimens were collected from the nasopharyngeal with sterile nasal swab, which was then fully pressed in a plastic pipe with diluents to solve the secretions. The solution was then dropped onto the test card, and the result was read after 15 minutes. If only the quality control line is a red color, the result is negative; if both the quality control line and the test line were red, the result is positive (Fig. 1).

HI test
HI method was used to detect the HI antibodies in three kinds of influenza subtypes, namely novel H1N1, seasonal H1N1 and seasonal H3N2. The antigen virus strains (Influenza virus antigen A1/Tianjin Jinnan/15/2009, A/SiChuan/
RESULTS

There were 73 patients enrolled in this study. Among them, 41 patients were male, 32 were female, mean age was 61.79 years (SDs 21.19).

GICA test

The nasopharyngeal secretion swab samples from 73 patients showing influenza like symptoms were subjected to rapid detection on Influenza A using the GICA method, 12 cases were positive, the positive rate was 16.4% (12/73). The positive patients included the following diagnoses: pneumonia (n=5), pneumocardial disease (n=4), lung cancer (n=1), interstitial pneumonia (n=1), asthmatic bronchitis (n=1).

The positive influenza patients were identified mainly during the September, October of 2009 (Table 1).

HI test

Twelve of the 73 patients show paired serum antibody level increased ≥4 times with half of them being novel H1N1 positive. Twenty-seven of the 73 patients show paired serum antibody level increased 2 times and most of them had season influenza (Table 2).

Comparisons in the positive results by GICA method and HI test

The 73 patients were subjected to rapid detection on Influenza A by using GICA method and paired serum antibody method, and the detection results from the two kinds of methods were subjected to McNemar test, $p=1.00$. The difference was not statistically significant. Consistency was checked using two kinds of methods: the Kappa value=0.402, indicating relatively good consistency. The results are shown in Table 3.

Evaluation indexes for diagnostic and detection data

Compared with the positive results in paired serum antibody, the sensitivity for rapid detection by using GICA was 50.0% and the specificity was 90.2%, the positive predict value was 50%, the negative predict value was 90.2% and the Youden index was 0.40.

DISCUSSION

The comparison of the GICA method and paired serum antibody method showed that the consistency of these two
kinds of methods were relatively good. If a patient with a fever was found to be positive for the Influenza A antigen using the GICA method and his specific antibody to paired serum A ratio showed an increase of four times at the same time, it was considered that Influenza A was the pathogen for the morbidity this time, but not the colonized virus in upper respiratory tract.

In this study, the positive results for the Influenza A antigen detection by using GICA method were mostly found in the group of pneumonia and chronic cor pulmonale patients, which was in accordance with the claim in the diagnostic criteria for type A influenza by the Ministry of Public Health in China, that people suffering from chronic respiratory disease are high-risk populations. The time of detection was mainly between September 2009 and March 2010, which was also in accordance to the spreading regularity of Influenza A. Furthermore, it was confirmed that the subtypes of novel type A H1N1 influenza in the Influenza A infected cases accounted for more than 50% of the cases, which satisfied the tendency that the novel type A H1N1 virus was the same as the epidemic strain in 2009. However, the cases showed an increase of two times the paired serum antibody and were mostly seasonal type A H1N1 and H3N2, indicating that diverging and spreading of seasonal type A influenza were not negligible.

In conclusion, sensitivity for Influenza A antigen detection based on GICA is relatively low and the specificity is relatively satisfactory, but it is a rapid and convenient method for diagnosis influenza A. This GICA-based influenza A rapid test may be helpful in managing influenza A epidemics in poorly resourced countries and community hospitals where PCR tests cannot be conveniently performed.

REFERENCES

1. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. Fields Virology. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. p.1487-531.
2. Hindiyeh M, Levy V, Azar R, Varsano N, Regev L, Shalev Y, et al. Evaluation of a multiplex real-time reverse transcriptase PCR assay for detection and differentiation of influenza viruses A and B during the 2001-2002 influenza season in Israel. J Clin Microbiol 2005;43:589-95.
3. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006;12:9-14.
4. Guan Y, Vijaykrishna D, Bahl J, Zhu H, Wang J, Smith GJ. The emergence of pandemic influenza viruses. Protein Cell 2010;1:9-13.
5. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009;459:1122-5.
6. Trifonov V, Khiabanian H, Greenbaum B, Rabadan R. The origin of the recent swine influenza A(H1N1) virus infecting humans. Euro Surveill 2009;14.pii:19193.
7. Dwyer DE, Smith DW, Catton MG, Barr IG. Laboratory diagnosis of human seasonal and pandemic influenza virus infection. Med J Aust 2006;185(10 Suppl):S48-53.
8. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics 2003;112:363-7.
9. World Health Organization. WHO recommendations on the use of rapid testing for influenza diagnosis. Available at: http://www.who.int/influenza/resources/documents/rapid_testing/en/.
10. Petric M, Comanor L, Petti CA. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis 2006;194 Suppl 2:S98-110.
11. Heeschen C, Goldmann BU, Moeller RH, Hamm CW. Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. Clin Chem 1998;44:1925-30.
12. Watanabe T, Ohkubo Y, Matsumoto H, Kimura H, Sakai Y, Okanu Y, et al. Development of a simple whole blood panel test for detection of human heart-type fatty acid-binding protein. Clin Biochem 2001;34:257-63.
13. Li X, Chen H, Wei J, Ly N, You L. The evaluation of colloidal gold immunochromatographic assay (GICA) for rapid diagnosis of influenza A disease. Clin Chem Lab Med 2011;49:1533-7.
14. Shafir SC, O’Keefe KA, Shaof KI. Evaluation of the seroprevalence of influenza A(H1N1) 2009 on a university campus: a cross-sectional study. BMC Public Health 2011;11:922.
15. Ministry of Health of the People's Republic of China. Program of diagnosis and treatment of influenza A H1N1(2010). Int J Respir 2011;31. (In Chinese)